Immunotherapy-refractory, EGFR overexpressing metastatic porocarcinoma responding to cetuximab

Eur J Cancer. 2021 Mar:146:84-86. doi: 10.1016/j.ejca.2021.01.012. Epub 2021 Feb 12.

Authors

Francesca Comito¹, Maria C Nigro², Francesca Sperandi³, Barbara Melotti³, Andrea Ardizzoni³

Affiliations

¹ Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy; Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital of Bologna, Bologna, Italy. Electronic address: francesca.comito2@unibo.it.
² Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital of Bologna, Bologna, Italy.
³ Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.

PMID: 33588148
DOI: 10.1016/j.ejca.2021.01.012

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents, Immunological / therapeutic use*
Cetuximab / therapeutic use*
Drug Resistance, Neoplasm / drug effects*
Eccrine Porocarcinoma / drug therapy*
Eccrine Porocarcinoma / immunology
Eccrine Porocarcinoma / metabolism
Eccrine Porocarcinoma / pathology
ErbB Receptors / genetics
ErbB Receptors / metabolism
Humans
Immunotherapy / adverse effects*
Male
Prognosis
Sweat Gland Neoplasms / drug therapy*
Sweat Gland Neoplasms / immunology
Sweat Gland Neoplasms / metabolism
Sweat Gland Neoplasms / pathology

Substances

Antineoplastic Agents, Immunological
EGFR protein, human
ErbB Receptors
Cetuximab